Artificial Intelligence & Analytical Innovation

--Enhance the Power of R Tools in Clinical Development

Qinghua Song

Kite Pharma, a Gilead Company Nov, 2019, R meetup, San Francisco

My Roles

- Clinical Study Statistician lead for phase 1 dose escalation and dose expansion study and Phase 2 pivotal study: be responsible for trial study designs, protocol development, SAP/DPP development, TLF review, SDTM and ADaM specs, interpretation of results, and preparation of inputs for regulatory documents
- Lead of AI2 (Artificial Intelligence & Analytical Innovation) Group, under Biometrics
 - Serve as a leading representative engaging on internal or external industry challenges like AI/machine/deep learning applications, advanced analytics and complex innovative designs
 - Lead/oversee projects which apply AI/machine/deep learning applications for Translational Research
 & Clinical Development (Artificial Intelligence part)
 - Lead/oversee creating tools and platforms that operationalize key methodology making diverse approaches available to study teams (Analytical Innovation part)

Use R not just for fun, but for real work! ☺

Statisticians Play Important Role in Model-Informed Drug Discovery and Development

Lead Life Cycle Target Selection and Preclinical Late Clinical Generation **Early Clinical** Management & Approval Validation Development Development Phase Therapeutic Development Optimization Use

Internal Decision Support

Regulatory Decision Support

Target Authorization & Mechanic Understanding

Candidate Comparison, Selection, Human PK & Dose Prediction

Study Design Optimization


Predicting & Characterizing ADME Including Intrinsic & Extrinsic Factors Impacting PK Variability

Risk/Benefit Characterization & Outcome Predication from Early Clinical Research

Dose & Schedule Selection & Label Recommendation (Including Drug Combination)

Comparator/Standard-of-Care Differentiation & Commercialization Strategies

Patient Population Selection & Bridging between Populations (Pediatric, elderly, Obese)



Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation., 2016, EFPIA MID3 Workgroup

What Analytical Tools to Use in Pharma?





In Pharma setting simulations vs. analysis exploratory vs. confirmatory


Advantages of using R in pharma


- Ability to create effective visualizations/ graphics
- Flexibility to combine with other tools/ own code
- Ability to bring new statistical methods and Machine Learning methods to the table very quickly
- As an open source environment it supports collaboration- and therefore innovation

Cytel blog: The Rise of R-should SAS programmers get up to speed?

Outstanding Graphical Outputs


- A picture is not merely worth a 1,000 words, it is much more likely to be scrutinized than words are to be read. – John Tukey
- "R is able to produce clean, ascetic charts suitable for journals and books and super fancy graphics perfect for presentations"
- R has great capability of making high quality of graphs with any kind.. and varied..







R Graph Gallery: Enhance your data visualization with R

...and Interactive Plots and Tables







The Shiny package uses R to build interactive web apps, an ideal data product to share, reduce iteration, allow clients to explore; provide a creative way in data visualization


The Markdown package build reports, documents, and presentations from R code: reproducible & dynamic

HTML W S

Biostatisticians can use Shiny and Markdown packages to create interactive data products straight from R; to create an ideal workflow for sharing data and results with clients and colleagues in Drug discovery and Development


Shiny App and R Markdown for Biomarker Analysis and Report


- Biomarkers, the key components in translational research, can be used for many purposes including diagnosis,
 prognosis and selecting appropriate patient therapy, and can provide information on disease mechanism or progression
- Currently most biomarker analyses are exploratory: time profiling, association, etc. TFLs are costly to produce and time consuming to review with multiple iterations.
- Multiple TFLs needed for a full exploratory research on different responses of different biomarkers, by different cohorts, groups and other variables
 - For analysts, It is time consuming with redundant coding
 - For scientists, it is not convenient to review these outputs one by one and easy to get lost.





With Shiny, biostatisticians can create R output from routine "Analytical Support"....












Al2 supporting Kite Biometrics' projects

...to "Analytical Innovation"

- Biomarker Explorer Shiny App:
- This R-shiny web app was developed for Translational statisticians and scientists to generate graphs and tables for biomarker exploratory analysis including time profiling, association and others, in an interactive platform.

Shiny + R Package provides efficient way to generate re-producible outputs



Highlight:

- Interactive graph displays
- Subset Analysis
- Creating output spec file
- Automatically producing TFLs



Generate Dynamic and Static Report for Exploratory Analysis

Shiny + Rmarkdown provides efficient way to generate reports in static or dynamic format

Efficient Statistical Tool Analysis Report (ESTAR) Coding outside of R Shiny or Markdown The R Shiny + Markdown Report writing


Summary

Report (html/PDF)

Qinghua Song, Feiyang Niu, and Yucheng Yang

Copyright @ 2017 Gilead Sciences, Inc. All rights reserved.


TFLs




Useful Shiny Apps for Drug R&D

Category	Shiny app	Description
Translational Research	Assay Development and Qualification	Graphs and tables for assay development and qualification.
	Biomarker Explorer	Graphs and tables for biomarker exploratory analysis including time profiling and association
	Predictive Biomarker Evaluation Tool	Implements STEPP and smooth curve visualization to assess trend of biomarker association with clinical outcome to facilitate identification of patient subgroup most likely to benefit from treatment
	Quartile Table	Summary (median, min and max for continuous parameters and frequency for discrete parameters) will be displayed by quartile.
Phase I	Phase 1 dose escalation	Visualization and exploration of pharmacokinetic and/or pharmacodynamic data
	PK Modeling	Model PKPD data along with quick diagnostic tools to evaluate model fit
Phase II & III	Oncology Topline Summary	Update in real time to the clinical team the key data of an on-going clinical trial including topline efficacy and safety results
	ClinPlot	Generate graphs for presentation purpose. The graphs include: CDF plot, forest plot, Kaplan Meier plot, Line plot, swimmer plot, waterfall plot and Venn Diagram.
	Event Projection	Predict when the pre-specified event milestones can be reached
	Predictive Power	Provide interactive way to estimate predictive power in various stages of clinical trials for various endpoints
Safety	Safety Monitoring & Graphics	Statistical methods for comparison and multiple control and to have interactive graphic display for Safety Monitoring

Selected Example apps developed by Biostatisticians from Gilead and Kite



Process for Shiny app development, validation, release, maintenance, and training



What Analytical Tools to Use in Pharma?






In Pharma setting simulations vs. analysis exploratory vs. confirmatory

Advantages of using R in pharma

- Ability to create effective visualizations/ graphics
- Flexibility to combine with other tools/ own code
- Ability to bring new statistical methods and Machine Learning methods to the table very quickly
- As an open source environment it supports collaboration- and therefore innovation

Cytel blog: The Rise of R-should SAS programmers get up to speed?

Tasks that need AI in Pharma industry



Kevin, H. BioIT, 2019

The Potential Benefits of Machine Learning in Clinical Trial and Drug Development

- identification of subgroup(s) with enhanced treatment benefit or identification of signatures highly correlated with clinical outcomes, by a combination of baseline clinical, biomarker and genomic factors in trial data
- As the number of biomarkers/features increases
 with technology advances, identifying a
 meaningful pattern raises particular statistical
 challenges within the context of limited sample
 sizes in clinical trials. Machine learning
 approaches (advanced regression and tree-based
 approaches etc.) applicable in exploratory setting
 to identify predictive signatures and subgroups

R Provides Advanced Statistical Programming Language for Machine Learning Projects and Clinical Trial

Current ongoing ML Projects in Al2 Group

Carrent ongoing with rojects in 742 Group					
Machine Learning Project	<u>R packages</u> for ML methods				
Machine Learning Platform for multivariate analysis: an end-to-end platform with multiple steps, which powers both self-service analytics and the operationalization of state-of-art machine learning models in an automatic and reproducible production	<u>caret, party</u> for Random Forest; <u>xgboost</u> for XgBoost <u>keras</u> , <u>LIME</u> for deep learning; <u>factoextra</u> for Principle Component <u>pls</u> for Partial Least Square; <u>ClustOfVar</u> for Hierachical Clustering; <u>pdp</u> for Partial Dependencey Plot; <u>ALEPlot</u> for Accumulated Local Effect plot				
Investigation and application of propensity score methods to clinical data and Real World data aiming to detect signals that may account for interested comparisons	<u>MatchIt</u> for Propensity Score Matching <u>WeightIt</u> for IPTW				
Application of causal learning with Bayesian network to explore the association and make causal inference of biomarkers and clinical outcomes	<u>bnlearn</u> for Bayesian network structure learning <u>sparsebn</u> for learning sparse Bayesian networks <u>igraph, gqdaq</u> for visualizing Bayesian networks				
Application of Generative Adversarial Networks (GANs) to	<u>keras</u> , implements almost all basic neural network layers, optimization				

Qinghua Song Ph.D.

generate synthetic data for clinical trial

R Pharma Meetup 2019

algorithms, loss functions, automatic gradient calculations

R Provides Advanced Statistical Programming Language for Machine Learning Projects and Clinical Trial


Current ongoing Projects for Clinical Trial Enhancement in Al2 Group

Projects for Clinical Trial Enhancement	<u>R packages</u> for Advanced Methods	
Prediction of Events and enrollments based on observed clinical data with consideration of accrual, event distribution and follow-up/drop-out.	<u>survival</u> for model regression/prediction <u>applot2</u> for generating observed/prediction curves <u>shiny, shinyjs, shinybs</u> for shiny app development.	
Generating frequently used clinical plots , including Kaplan-Meier plot, swimmer plot, waterfall plot and forest plot.	<u>shiny, colourpicker, gridextra, shinyjs, shinybs</u> for shiny app development. <u>survival, survminer, metafor, Hmisc</u> for survival-related plot element. <u>ggplot2, gridextra, scales, grid</u> for generating plots_	
Deep dive into Bayesian Optimal Interval (BOIN) Design, a novel phase I clinical trial design to fine maximum tolerated dose.	BOIN for trial design and simulation.	
Mixture Cure Model with cox survival and logistic regression cure rate is implemented to discover potential cure effect from certain biomarker.	Modified CRAN package <u>smcure</u> is used.	

Multivariate Analysis Platform (MAP)

Goal of Analysis:

- Discovering Patterns of Biomarkers; Understanding Clusters
- Characterizing association of Biomarkers with outcomes
- Predictive Modeling, Model evaluation, cut-off selection



A Step-by-step Easy-to-use Workflow

Multivariate Analysis Platform Workflow

Jin Xie¹, Tao Hu¹ and Qinghua Song¹

¹Kite Pharma, A Gilead Company

October 23, 2019

Abstract

MAP (Multivariate Analysis Platform) is a multivariate analysis and machine learning platform developed by Artificial Intelligence & Analytical Innovation group for internal usage. This platform aims to provide analytical support for business questions, to pattern and cluster the covariates; to find the association of covariates with outcomes; and to build a predictive model. MAP is a collaborative platform which powers both self-service analytics and the operationalization of state-of-art machine learning models in an automatic and reproducible production. It is an end to end platform with multiple steps from data pro-precessing, imputation, feature selection to statistical modeling, interpretation and model evaluation. This document provides step-by-step introduction on the major functionalities of the package. Example codes and results can be found within each section.

Contents

- 1 Introduction
- 2 Reproducibility
- 3 Data Preparation
- 4 Univariate Screening
- 5 Variable Importance Ranking
 - 5.1 Data Imputation
 - 5.2 Variable Importance by Conditional Random Forest
 - 5.2.1 The details of obtaining the Variable Importance by Cforest
 - 5.2.2 Model Training by Cforest
 - 5.2.3 Variable Pre-elimination
 - 5.3 Variable Importance by Extreme Gradient Boosting (XGBoost)
 - 5.3.1 Advantages of XGboost
 - 5.3.2 Model Training by XGboost
 - 5.3.3 Setting Customized Parameters
- 6 Feature Selection
- 7 Modeling and Evaluation
- 8 Interpretation and Visualization
 - 8.1 Single Conditional Inference Tree
 - 8.2 Partial Dependence Plot
 - 8.3 Accumulated Local Effects Plot
 - 8.4 Principal Component Analysis
 - 8.5 Partial Least Squares
 - 8.6 Clustering of Variables

From Multiple Folders to a Single Shiny app; From Being Static to Being Dynamic and Interactive

L 2_imp_cforest_seed	8/14/2019 12:51 PM	File folder	
👢 3_pred_result	8/14/2019 12:51 PM	File folder	
👢 4_Partial_Dependence_Plot	8/14/2019 12:51 PM	File folder	
lmportance	8/14/2019 12:51 PM	File folder	
🔊 0_data_imputed	8/13/2019 10:16 AM	Microsoft Excel Com	35 KB
1_Univaraite_Screen	8/13/2019 10:11 AM	Microsoft Excel Com	4 KB
2_imp_cforest_average50	8/13/2019 1:09 PM	Microsoft Excel Com	66 KB
2_imp_cforest_average50_summary	8/13/2019 1:09 PM	Microsoft Excel Com	2 KB
2_RF_backward_selection	8/13/2019 2:52 PM	Microsoft Excel Com	1 KB
a 2_RF_final_selection	8/13/2019 2:52 PM	Microsoft Excel Com	1 KB
2_RF_selection	8/13/2019 2:52 PM	Adobe Acrobat Doc	6 KB
2_var_imp	8/13/2019 2:50 PM	Adobe Acrobat Doc	13 KB
3_backward_overall_coef	8/13/2019 4:03 PM	Microsoft Excel Com	1 KB
3_backward_penalized_regression	8/13/2019 4:03 PM	Adobe Acrobat Doc	6 KB
3_backward_penalized_regression_label	8/13/2019 4:03 PM	Adobe Acrobat Doc	6 KB
3_backward_penalized_regression_result	8/13/2019 4:03 PM	Microsoft Excel Com	2 KB
4_cforest_all.fit	8/13/2019 4:44 PM	FIT File	9,481 KB
5_PCA_pcs	8/13/2019 5:30 PM	Microsoft Excel Com	1 KB
5_PCA_plots	8/13/2019 5:30 PM	Adobe Acrobat Doc	11 KB
5_PCA_variable_loadings	8/13/2019 5:30 PM	Microsoft Excel Com	7 KB
5_PLS_plots	8/13/2019 5:32 PM	Adobe Acrobat Doc	9 KB
5_PLS_variable_loadings	8/13/2019 5:32 PM	Microsoft Excel Com	7 KB
5_PLS_VIP	8/13/2019 5:32 PM	Microsoft Excel Com	1 KB
6_PCA_clustering_groups	8/13/2019 5:34 PM	Microsoft Excel Com	1 KB
6_PCA_clustering_plots	8/13/2019 5:34 PM	Adobe Acrobat Doc	9 KB



Currently, all the outputs are saved in a folder

A shiny app is under development to help reviewing and saving outputs more efficiently

- Organize outputs in a better structure than multiple folders
- Demonstrate outputs more dynamically and interactively

Discussion

- Biostatisticians need to be on top of cutting-edge methodologies and technologies
- Should we pursue building high-quality cross-platform apps with fancier design, more complete/complex setting, more customized functions, to fulfill ALL needs, in a more professional setting?
- Should we propose and expand the implement of R in submission?
- What we can do:
 - Bring in more robust and validated R products/platforms which offer complete deployment flexibility with unrestricted server activations
 - Build Cloud environment which enables collecting, storing and analyzing huge amount of data; faster speed of installing software and transferring data; more convenient way to use existing service (AzureML, for example)

Acknowledgement

- Kite AI2 group (Qinghua Song, Bella Feng, Jin Xie, Tao Hu, Shengchao Hou, Allen Xue)
- Kite Biometrics (Lianqing Zheng, Jennifer Sun, Yin Yang, Rajesh Venkkataram, Joe Jiang)
- Kite IT (Ben Lam, Nikki Nguyen, Peter Taing, Sepehr Dadsetan)
- Gilead Center of Excellence (Ron Yu, Shuo Wang)
- Gilead Biometrics (Jing Hu, Zhisheng Ye, Xiaomin Lu, Neby Bekele)
- Gilead R Platform (Niall Mcsharry, Kaiding Zhu)